KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $3.6 million.

  • Castle Biosciences' Change in Accured Expenses rose 47.43% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 28.82%. This contributed to the annual value of $3.6 million for FY2024, which is 21.30% down from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Change in Accured Expenses is $3.6 million, which was down 21.30% from $4.6 million recorded in FY2023.
  • Castle Biosciences' Change in Accured Expenses' 5-year high stood at $8.5 million during FY2022, with a 5-year trough of $3.3 million in FY2020.
  • For the 3-year period, Castle Biosciences' Change in Accured Expenses averaged around $5.6 million, with its median value being $4.6 million (2023).
  • In the last 5 years, Castle Biosciences' Change in Accured Expenses skyrocketed by 175.58% in 2020 and then plummeted by 46.00% in 2023.
  • Castle Biosciences' Change in Accured Expenses (Yearly) stood at $3.3 million in 2020, then skyrocketed by 86.48% to $6.2 million in 2021, then spiked by 36.84% to $8.5 million in 2022, then plummeted by 46.00% to $4.6 million in 2023, then dropped by 21.30% to $3.6 million in 2024.